S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Stock market today: Asian shares mixed, with most regional markets closed after Wall St ticks higher
66,000% upside on tiny biotech? (Ad)
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Low Beta Stocks To Offset A Possible Hard Landing
The single greatest medical breakthrough of all time? (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
The single greatest medical breakthrough of all time? (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Stock market today: Asian shares mixed, with most regional markets closed after Wall St ticks higher
66,000% upside on tiny biotech? (Ad)
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Low Beta Stocks To Offset A Possible Hard Landing
The single greatest medical breakthrough of all time? (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
The single greatest medical breakthrough of all time? (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Stock market today: Asian shares mixed, with most regional markets closed after Wall St ticks higher
66,000% upside on tiny biotech? (Ad)
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Low Beta Stocks To Offset A Possible Hard Landing
The single greatest medical breakthrough of all time? (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
The single greatest medical breakthrough of all time? (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Stock market today: Asian shares mixed, with most regional markets closed after Wall St ticks higher
66,000% upside on tiny biotech? (Ad)
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Low Beta Stocks To Offset A Possible Hard Landing
The single greatest medical breakthrough of all time? (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
The single greatest medical breakthrough of all time? (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Forecast, Price & News

$4.08
+0.03 (+0.74%)
(As of 09/28/2023 ET)
Compare
Today's Range
$3.93
$4.10
50-Day Range
$3.10
$5.35
52-Week Range
$2.81
$13.40
Volume
14,870 shs
Average Volume
22,614 shs
Market Capitalization
$15.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.00

Akari Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,248.0% Upside
$55.00 Price Target
Short Interest
Healthy
0.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Akari Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

642nd out of 969 stocks

Pharmaceutical Preparations Industry

305th out of 455 stocks


AKTX stock logo

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Price History

AKTX Stock News Headlines

StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)
1907, 1929, 1998, 2007--and now 2023?
Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.
Akari Therapeutics to Present at Emerging Growth Conference
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
British pharma opens U.S. headquarters in Boston
Akari Therapeutics, Plc Announces ADS Ratio Change
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings
3/31/2020
Today
9/29/2023
Next Earnings (Estimated)
9/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKTX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+1,248.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
1,422,000
Market Cap
$15.19 million
Optionable
Not Optionable
Beta
1.40
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Ms. Rachelle Suzanne Jacques (Age 52)
    Pres, CEO & Director
    Comp: $1.38M
  • Ms. Wendy F. DiCicco CPA (Age 56)
    CPA, Interim Chief Financial Officer
  • Ms. Melissa Bradford-Klug (Age 53)
    Chief Operating Officer
  • Dr. Miles Nunn (Age 54)
    Chief Scientific Officer
  • Dr. John F. Neylan III (Age 70)
    M.D., Exec. VP & Chief Medical Officer
  • Ms. Beth-Anne Lang
    Sr. VP of Regulatory Affairs
  • Annie Mack
    Financial Controller













AKTX Stock - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings
or view top-rated stocks.

What is Akari Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued 1 year target prices for Akari Therapeutics' shares. Their AKTX share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's stock price to reach $55.00 in the next twelve months. This suggests a possible upside of 1,248.0% from the stock's current price.
View analysts price targets for AKTX
or view top-rated stocks among Wall Street analysts.

How have AKTX shares performed in 2023?

Akari Therapeutics' stock was trading at $9.3980 at the beginning of the year. Since then, AKTX stock has decreased by 56.6% and is now trading at $4.08.
View the best growth stocks for 2023 here
.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 17,100 shares, an increase of 116.5% from the August 31st total of 7,900 shares. Based on an average daily volume of 30,800 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.5% of the shares of the company are sold short.
View Akari Therapeutics' Short Interest
.

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, September 29th 2023.
View our AKTX earnings forecast
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) released its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics shares reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?
What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $4.08.

How much money does Akari Therapeutics make?

Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $15.19 million. The biopharmaceutical company earns $-17,750,000.00 in net income (profit) each year or ($7.00) on an earnings per share basis.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -